期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/ijms231912032
关键词
breast cancer; in vitro studies; nanoformulations; omega-3 PUFA; ovarian cancer; preclinical studies
资金
- Universita Cattolica del S. Cuore
- Rome, Italy
- Department of Pharmacy and Health and Nutrition Sciences
This article critically analyzes the results of recent studies investigating the effects of omega-3 PUFA-containing nanoformulations in breast cancer and ovarian cancer. The studies show that omega-3 PUFAs have anti-inflammatory, antiangiogenic, and antitumor effects, and can enhance drug delivery and minimize side effects. These findings provide a theoretical basis for further interventional clinical trials.
Different strategies have been investigated for a more satisfactory treatment of advanced breast cancer, including the adjuvant use of omega-3 polyunsaturated fatty acids (PUFAs). These nutritional compounds have been shown to possess potent anti-inflammatory and antiangiogenic activities, the capacity to affect transduction pathways/receptors involved in cell growth and to reprogram tumor microenvironment. Omega-3 PUFA-containing nanoformulations designed for drug delivery in breast cancer were shown to potentiate the effects of enclosed drugs, enhance drug delivery to target sites, and minimize drug-induced side effects. We have critically analyzed here the results of the most recent studies investigating the effects of omega-3 PUFA-containing nanoformulations in breast cancer. The anti-neoplastic efficacy of omega-3 PUFAs has also been convincingly demonstrated by using preclinical in vivo models of ovarian cancer. The results obtained are critically analyzed here and seem to provide a sufficient rationale to move to still lacking interventional clinical trials, as well as to evaluate possible advantages of enclosing omega-3 PUFAs to drug-delivery nanosystems for ovarian cancer. Future perspectives in this area are also provided.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据